Efficient induction of cytotoxic T lymphocytes specific to hepatocellular carcinoma using HLA-A2-restricted MAGE-n peptide in vitro

Cancer Letters

Volumn 211, Issue 2, 2004, Pages 219-225

  Dong, Hai Long ^a   Sui, Yan Fang ^a   Li, Zeng Shan ^a   Qu, Ping ^a   Wu, Wen ^a   Ye, Jing ^a   Zhang, Xiu Min ^a   Lu, Shao Ying ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Cytotoxic T lymphocytes; Hepatocellular carcinoma; HLA A2; MAGE n

Indexed keywords

HLA A2 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MONOCLONAL ANTIBODY; PEPTIDE;

ANTIGEN SPECIFICITY; ARTICLE; CELL STIMULATION; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; IMMUNOTHERAPY; IN VITRO STUDY; LIVER CELL CARCINOMA; MOLECULAR RECOGNITION; MONONUCLEAR CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CARCINOMA, HEPATOCELLULAR; CELL LINE; HLA-A2 ANTIGEN; HUMANS; IMMUNOTHERAPY; LIVER NEOPLASMS; LYMPHOCYTE ACTIVATION; NEOPLASM PROTEINS; PEPTIDES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 3042606375     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2004.02.013     Document Type: Article

References (20)

1. Boel P., Wildmann C., Sensi M.L., Renauld J.C., Coulie P., Boon T., et al. BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity. 2:1995;167-175
2. van der Bruggen P., Traversari C., Chomez P., Lurquin C., De Plaen E., Van den Eynde B., et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 254:1991;1643-1647
3. Katsura F., Eura M., Chikamatsu K., Oiso M., Yumoto E., Ishikawa T. Analysis of individual specific cytotoxic T lymphocytes for two MAGE-3-derived epitopes presented by HLA-A24. Jpn. J. Clin. Oncol. 30:2000;117-121
4. Renkvist N., Castelli C., Robbins P.F., Parmiani G. A listing of human tumor antigens recognized by T cells. Cancer Immunol. Immunother. 50:2001;3-15
5. Li J., Yang Y., Fujie T., Baba K., Ueo H., Mori M., et al. Expression of BAGE, GAGE, and MAGE genes inhuman gastric carcinoma. Clin. Cancer Res. 2:1996;1619-1625
6. Wu W., Sui Y.F., Ye J., Li Z.S., Guo A.L., Yang X.W., et al. The cloning of tumor-associated gene MAGE in human heptatocellular carcinoma cell line. Chin. J. Cell. Mol. Immunol. 18:2002;270-274
7. Nguyen M.H., Keeffe E.B. Screening for hepatocellular carcinoma. J. Clin. Gastroenterol. 35:2002;S86-S91
8. Butterfield L.H., Ribas A. Immunotherapy of hepatocellular carcinoma. Expert Opin. Biol. Ther. 2:2002;123-133
9. Ladhams A., Schmidt C., Sing G., Butterworth L., Fielding G., Tesar P., et al. Treatment of non-resectable hepatocellular carcinoma with autologous tumor-pulsed dendritic cells. J. Gastroenterol. Hepatol. 17:2002;889-896
10. Ming L.H., Zhu Y.R., Harris C.C., Wang X.H., Wu Z.Y., Sun Z.T. Association of HLA-A02 genotype with hepatocellular carcinoma in a prevalent area of China. Chin. J. Immunol. 15:1999;305-310
11. Rammensee H.G., Bachmann J., Emmerich N.P.N., Bachor O.A., Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics. 50:1999;213-219
12. Parker K.C., Bednarek M.A., Coligan J.E. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide sidechains. J. Immunol. 152:1994;163-175
13. Molldrem J.J., Lee P.P., Wang C., Champlin R.E., Davis M.M. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Res. 59:1999;2675-2681
14. Andersen M.H., Keikavoussi P., Brocker E.B., Schuler T.B., Jonassen M., Sondergaard I., et al. Induction of systemic CTL responses in melanoma patients by dendritic cell vaccination: cessation of CTL responses is associated with disease progression. Int. J. Cancer. 94:2001;820-824
15. Brossart P., Wirths S., Stuhler G., Reichardt V.L., Kanz L., Brugger W. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood. 96:2000;3102-3108
16. Eifuku R., Takenoyama M., Yoshino I., Imahayashi S., So T., Yasuda M., et al. Analysis of MAGE-3 derived synthetic peptide as a human lung cancer antigen recognized by cytotoxic T lymphocytes. Int. J. Clin. Oncol. 6:2001;34-39
17. Graff-Dubois S., Faure O., Gross D.A., Alves P., Scardino A., Chouaib S., et al. Generation of CTL recognizing an HLA-A*0201- restricted epitope shared by MAGE-A1, -A2, -A3, -A4, -A6, -A10, and -A12 tumor antigens: implication in a broad-spectrum tumor immunotherapy. J. Immunol. 169:2002;575-580
18. Katsura F., Eura M., Chikamatsu K., Oiso M., Yumoto E., Ishikawa T. Analysis of individual specific cytotoxic T lymphocytes for two MAGE-3-derived epitopes presented by HLA-A24. Jpn. J. Clin. Oncol. 30:2000;117-121
19. Plebanski M., Allsopp C.E., Aidoo M., Reyburn H., Hill A.V. Induction of peptide-specific primary cytotoxic T lymphocyte responses from human peripheral blood. Eur. J. Immunol. 25:1995;1783-1787
20. Tanaka F., Fujie T., Go H., Baba K., Mori M., Takesako K., et al. Efficient induction of antitumor cytoxic T lymphocytes from a healthydonor using HLA-A2-restricted MAGE-3 peptide in vitro. Cancer Immunol. Immunother. 44:1997;21-26